Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
INNV vs DBVT vs ALKS vs ALHC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Healthcare Plans
INNV vs DBVT vs ALKS vs ALHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Healthcare Plans |
| Market Cap | $1.10B | $1712.35T | $5.90B | $3.73B |
| Revenue (TTM) | $946M | $0.00 | $1.56B | $4.26B |
| Net Income (TTM) | $-22M | $-168M | $153M | $20M |
| Gross Margin | 14.8% | — | 65.4% | 9.0% |
| Operating Margin | 1.5% | — | 12.3% | 0.8% |
| Forward P/E | 32.0x | — | 24.8x | 140.9x |
| Total Debt | $101M | $22M | $70M | $338M |
| Cash & Equiv. | $64M | $194M | $1.12B | $578M |
INNV vs DBVT vs ALKS vs ALHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| InnovAge Holding Co… (INNV) | 100 | 31.3 | -68.7% |
| DBV Technologies S.… (DBVT) | 100 | 37.5 | -62.5% |
| Alkermes plc (ALKS) | 100 | 189.5 | +89.5% |
| Alignment Healthcar… (ALHC) | 100 | 83.2 | -16.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INNV vs DBVT vs ALKS vs ALHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INNV is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.66
- +147.9% vs ALKS's +16.5%
DBVT lags the leaders in this set but could rank higher in a more targeted comparison.
ALKS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Lower P/E (24.8x vs 140.9x)
- 9.8% margin vs INNV's -2.3%
- 5.4% ROA vs DBVT's -89.0%
ALHC is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 5.4% 10Y total return vs ALKS's -11.0%
- Beta 0.75, current ratio 1.74x
- 46.1% revenue growth vs DBVT's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (24.8x vs 140.9x) | |
| Quality / Margins | 9.8% margin vs INNV's -2.3% | |
| Stability / Safety | Beta 0.75 vs INNV's 1.66 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +147.9% vs ALKS's +16.5% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
INNV vs DBVT vs ALKS vs ALHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INNV vs DBVT vs ALKS vs ALHC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
ALHC leads 1 • INNV leads 0 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALHC and DBVT operate at a comparable scale, with $4.3B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to INNV's -2.3%. On growth, ALHC holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $946M | $0 | $1.6B | $4.3B |
| EBITDAEarnings before interest/tax | $4M | -$112M | $212M | $66M |
| Net IncomeAfter-tax profit | -$22M | -$168M | $153M | $20M |
| Free Cash FlowCash after capex | $39M | -$151M | $392M | $237M |
| Gross MarginGross profit ÷ Revenue | +14.8% | — | +65.4% | +9.0% |
| Operating MarginEBIT ÷ Revenue | +1.5% | — | +12.3% | +0.8% |
| Net MarginNet income ÷ Revenue | -2.3% | — | +9.8% | +0.5% |
| FCF MarginFCF ÷ Revenue | +4.1% | — | +25.1% | +5.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.5% | — | +28.2% | +33.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -161.3% | +91.5% | -4.1% | +2.1% |
Valuation Metrics
Evenly matched — ALKS and ALHC each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, ALKS's 17.3x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.1B | $1712.35T | $5.9B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $1712.35T | $4.9B | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | -36.73x | -0.76x | 24.76x | -4932.43x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.03x | — | — | 140.93x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.25x | 77.12x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | — | 4.00x | 0.94x |
| Price / BookPrice ÷ Book value/share | 4.16x | 0.66x | 3.28x | 20.16x |
| Price / FCFMarket cap ÷ FCF | 41.22x | — | 12.28x | 32.95x |
Profitability & Efficiency
ALKS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALHC delivers a 11.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -8.2% | -130.2% | +8.8% | +11.5% |
| ROA (TTM)Return on assets | -4.1% | -89.0% | +5.4% | +1.8% |
| ROICReturn on invested capital | -6.8% | — | +18.9% | — |
| ROCEReturn on capital employed | -7.1% | -145.7% | +14.2% | +2.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.38x | 0.13x | 0.04x | 1.89x |
| Net DebtTotal debt minus cash | $37M | -$172M | -$1.0B | -$240M |
| Cash & Equiv.Liquid assets | $64M | $194M | $1.1B | $578M |
| Total DebtShort + long-term debt | $101M | $22M | $70M | $338M |
| Interest CoverageEBIT ÷ Interest expense | 5.96x | -189.82x | 32.30x | 1.27x |
Total Returns (Dividends Reinvested)
ALHC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, INNV leads with a +147.9% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +55.7% | +4.9% | +25.3% | -9.7% |
| 1-Year ReturnPast 12 months | +147.9% | +110.4% | +16.5% | +17.6% |
| 3-Year ReturnCumulative with dividends | +24.5% | +19.7% | +14.5% | +152.4% |
| 5-Year ReturnCumulative with dividends | -68.5% | -69.1% | +60.9% | -22.7% |
| 10-Year ReturnCumulative with dividends | -66.6% | -87.0% | -11.0% | +5.4% |
| CAGR (3Y)Annualised 3-year return | +7.6% | +6.2% | +4.6% | +36.2% |
Risk & Volatility
Evenly matched — ALKS and ALHC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALHC is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than INNV's 1.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs INNV's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.66x | 1.26x | 1.06x | 0.75x |
| 52-Week HighHighest price in past year | $10.68 | $26.18 | $36.60 | $23.87 |
| 52-Week LowLowest price in past year | $2.85 | $7.53 | $25.17 | $11.63 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +76.3% | +96.7% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 48.1 | 60.2 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 291K | 252K | 2.3M | 3.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INNV as "Hold", DBVT as "Buy", ALKS as "Buy", ALHC as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -15.8% for INNV (target: $7).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.80 | $46.33 | $44.00 | $24.83 |
| # AnalystsCovering analysts | 8 | 15 | 28 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | +0.5% | 0.0% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALHC leads in 1 (Total Returns). 2 tied.
INNV vs DBVT vs ALKS vs ALHC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INNV or DBVT or ALKS or ALHC a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INNV or DBVT or ALKS or ALHC?
On forward P/E, InnovAge Holding Corp.
is actually cheaper at 32. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INNV or DBVT or ALKS or ALHC?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ALHC returned +5. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INNV or DBVT or ALKS or ALHC?
By beta (market sensitivity over 5 years), Alignment Healthcare, Inc.
(ALHC) is the lower-risk stock at 0. 75β versus InnovAge Holding Corp. 's 1. 66β — meaning INNV is approximately 122% more volatile than ALHC relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INNV or DBVT or ALKS or ALHC?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INNV or DBVT or ALKS or ALHC?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -3. 6% for InnovAge Holding Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -3. 5% for INNV. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INNV or DBVT or ALKS or ALHC more undervalued right now?
On forward earnings alone, InnovAge Holding Corp.
(INNV) trades at 32. 0x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 108. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — INNV or DBVT or ALKS or ALHC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INNV or DBVT or ALKS or ALHC better for a retirement portfolio?
For long-horizon retirement investors, Alignment Healthcare, Inc.
(ALHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). InnovAge Holding Corp. (INNV) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALHC: +5. 4%, INNV: -66. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INNV and DBVT and ALKS and ALHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INNV is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.